1 An evaluation of global Chikungunya clinical management guidelines – a systematic

- 2 review
- 3 Authors:
- 4 Eika Webb, MBBS,¹, ORCID: 0000-0002-6506-3489
- 5 Melina Michelen,* MSc,² ORCID: 0000-0003-3659-7788
- 6 Ishmeala Rigby, * MSc,² ORCID: 0000-0001-9236-7317
- 7 Andrew Dagens, MRCP,² ORCID: 0000-0003-4982-6690
- 8 Dania Dahmash, PhD, ² ORCID: 0000-0001-6508-0994
- 9 Vincent Cheng, DPhil,⁴ ORCID:0000-0002-6162-4146
- 10 Reena Joseph, MSc,³ ORCID: 0000-0001-8071-0763
- 11 Samuel Lipworth, MBBS, ^{5,6} ORCID: 0000-0001-5872-9214
- 12 Eli Harriss, BSc,⁷
- 13 Erhui Cai, DPhil,²
- 14 Robert Nartowski, MA²
- 15 Pande Putu Januraga, DrPH,¹² ORCID:0000-0002-2926-0856
- 16 Keerti Gedela, FRCP/MRCP, ³ORCID: 0000-0002-5797-8216
- 17 Evi Sukmaningrum, PhD, ^{10,11} ORCID: 0000-0001-8885-7823
- 18 Helen Groves, PhD⁸ ORCID: 0000-0002-5594-9526
- 19 Peter Hart, PhD⁸ ORCID: 0000-0001-8606-7932
- 20 Tom Fletcher, PhD, ¹ ORCID: 0000-0002-3712-415X
- 21 Lucille Blumberg, MMed⁹ ORCID: 0000-0002-2828-7678
- 22 Peter Horby, FRCP, ² ORCID: 0000-0002-9822-1586
- 23 Shevin T Jacob,** MD MPH¹, ORCID: 0000-0003-2425-9394

24 Louise Sigfrid,** PhD, ² ORCID: 0000-0003-2764-1177

- 25
- 26 * Joint second authors
- 27 **Joint senior authors
- 28 ¹Liverpool School of Tropical Medicine, Pembroke Pl, Liverpool, UK
- 29 ² International Severe Acute Respiratory and emerging Infection Consortium, Centre for Tropical
- 30 Medicine, University of Oxford, Oxford, UK
- 31 ³ Imperial College London, London, UK
- 32 ⁴ Bristol Medical School, University of Bristol, Bristol, UK
- 33 ⁵ Oxford University Hospitals NHS Foundation Trust, Oxford, UK
- 34 ⁶ Nuffield Department of Medicine, University of Oxford, Oxford, UK
- 35 ⁷ Bodleian Health Care Libraries, University of Oxford, Oxford, UK
- 36 ⁸Wellcome Trust, 183 Euston Rd, London, UK
- 37 ⁹ National Institute for Communicable Diseases, South Africa
- 38 ¹⁰ Atma Jaya Catholic University of Indonesia, Indonesia
- 39 ¹¹ HIV AIDS Research Centre-HPSI, AJCU
- 40 ¹² Udayana University, Bali, Indonesia

41 Abstract

42	Background: Chikungunya virus (CHIKV) has expanded its geographical reach in recent decades and is
43	an emerging global health threat. CHIKV can cause significant morbidity and lead to chronic, debilitating
44	arthritis in up to 40% of infected individuals, impacting on livelihoods. Prevention, early identification,
45	and clinical management are key for improving outcomes. This review aims to evaluate the availability of
46	inclusive, evidence-based clinical management guidelines for CHIKV in a global context.
47	
48	Methods: Six databases were searched systematically from inception to 14th October 2021 and
49	complemented with a grey literature search until 16th September 2021. We included CMGs providing
50	supportive care and treatment recommendations. Two reviewers independently screened records,
51	extracted data and assessed quality using the AGREE II tool. Findings are presented in a narrative
52	synthesis.
53	
54	Results: Twenty-eight CMGs were included; most were of low-quality (median score 2 out of 7 (range
55	1-7)). None were produced specifically in a low-income country and 54% (15/28) were produced more
56	than five years ago. There were variations in the CMGs' guidance on the management of different at-risk
57	populations, long-term sequelae, and the prevention of disease transmission in community and hospital
58	settings. In the acute phase, 54% (15/28) recommended hospitalisation for severe cases, however only
59	39% (11/28) provided clinical management guidance for severe disease. Further, 46% (13/28) advocated
60	for steroids in the chronic phase, yet 18% (5/28) advised against its use.
61	
62	Conclusion: There was a lack of high-quality CMGs that provided supportive care and treatment
63	guidance; this scarcity may impact patient care and outcomes. It is essential that existing guidelines are
64	updated and adapted to provide detailed evidence-based treatment guidelines for different at-risk
65	populations. This study also highlights a need for more research into the management of the acute and

66 chronic phases of CHIKV infection to inform evidence-based care.

67	
68	Systematic review registration: PROSPERO CRD42020167361
69	Keywords: Clinical management guidelines, AGREE II, Supportive care, Chikungunya, Emerging
70	infections,
71	
72	What was known before
73	• CHIKV is endemic across most of the southern hemisphere, with risk of expansion into new
74	regions driven by global travel, trade, and climate change.
75	
76	• Infection can result in severe illness with long-term sequelae, particularly in vulnerable groups.
77	Chronic sequelae of CHIKV infection is a cause of significant debilitating morbidity affecting
78	individual functionality and quality of life with wider health system and socio-economic impact.
79	
80	• There is no effective vaccine or targeted treatment against Chikungunya and supportive care is
81	the mainstay of treatment.
82	
83	• Even with a limited evidence base, clinical management guidelines (CMGs) are key tools for
84	standardising best available evidence-based care, and reduce inappropriate use of treatments, to
85	reduce morbidity and improve patient outcomes.
86	
87	What this study adds
88	• This review highlights a global scarcity of CMGs for chikungunya providing detailed guidance
89	on optimal supportive care and treatment for different at-risk populations and settings.
90	

91	٠	There was limited guidance available on care for severe cases, and available guidance was
92		heterogenous and discordant (e.g., on use of analgesia, corticosteroids, and monitoring).
93		
94	•	The limited availability of up-to-date CMGs and heterogenous recommendations identified is a
95		concern, which may impact on equity in access to best available evidence-based care and patient
96		outcomes.
97		
98	•	Further research into access to and implementation of CMGs in different settings is needed, to
99		ensure equitable access to best available care.
100		
101	•	This study also highlights a need for further investment into research into supportive care and
102		treatment for different at-risk populations, and new evidence incorporated into guidelines to
103		reduce morbidity and improve long term outcomes for the people affected by and at risk of
104		Chikungunya.
105		
106		
107		
108		
109		
110		
111		
112		
113		
114		
115		

116 INTRODUCTION

117 Chikungunya is a disease caused by the chikungunya virus (CHIKV); an arthropod-borne virus 118 transmitted to humans primarily by Aedes mosquitoes. Since its description in 1952, CHIKV has caused 119 millions of human infections in Africa, the Indian Ocean islands, Asia, Europe, and the Americas.¹ A 120 major outbreak in 2004 affected more than 100 countries with over 10 million cases and this was followed 121 by another large outbreak in 2013 in the Americas.² Multiple factors have contributed to these outbreaks 122 including a lack of vaccines and effective treatments, limited mosquito control in densely populated urban 123 areas, and climate changes.³ It is estimated that 1.3 billion people live in areas at risk of CHIKV 124 infection.^{4,5} Modelling studies of climate change, indicate that regions such as Europe are at risk of 125 introduction of CHIKV in the future.^{4,6,7} The recent and projected expansion in geographical range and 126 risk of travel-imported infections, with risk of local outbreaks during favourable transmission conditions 127 have increased CHIKV's recognition as an emerging global health threat.

128

129 Chikungunya has a wide spectrum of clinical presentations, which can be classified into three phases 130 (acute, sub-acute and chronic).⁸ Acute CHIKV (classed as less than three weeks post onset of symptoms) 131 manifests as a febrile illness with predominant symptoms of polyarthralgia, rash, and headache. This can 132 be followed by a subacute phase lasting up to three months.⁹ An estimated 40% of people are affected by 133 long-term chronic sequelae defined as persistent symptoms more than 3 months post-onset, for up to 6 vears.^{9,10} The chronic manifestations of CHIKV include debilitating symptoms of chronic arthralgia. 134 135 arthritis, fatigue which may lead to disability and diminished quality of life,¹¹ with severe impact on an 136 individual's ability to work. Although the acute infection is self-limiting and rarely life-threatening, it can 137 result in severe illness and mortality particularly in neonates, older adults (over 65 years) and people with comorbidities. ^{2,8,12–14} To date, there is no specific treatment approved for acute or chronic chikungunya 138 139 illness; although vaccines have been developed and tested in humans, none are vet available.^{15,16} Thus, to 140 improve patient outcomes, and reduce the chronic burden; supportive care is essential for the clinical 141 management of chikungunya.¹⁷

6

142	Parallels can be drawn between CHIKV, and SARS-CoV-2 given that both viruses can cause acute illness
143	followed by long-term sequelae in survivors, which can have a devastating impact on individuals'
144	psychological and physical health and capacity to return to work. Accordingly, public health
145	interventions adopted by many countries to slow the spread of COVID-19 (i.e., reduction in the number
146	of regular household surveys; diversion of resources towards the COVID-19 response; lockdowns) may
147	likely have had a negative impact on vector surveillance and control. ^{18,19} As we are transitioning out of
148	the pandemic, we need to prepare to shift resources to identify and mitigate the wider pandemic
149	consequences and strengthen our capacity to respond to future epidemics.
150	
151	CHIKV infection is a serious global public health problem, predominantly affecting populations and
152	health systems in lower resourced settings, and with risk of importation into new, naïve regions. The aim
153	of this review is to explore the availability and accessibility of evidence-based clinical management
154	guidelines for chikungunya globally and evaluate their quality and harmonisation of treatment
155	recommendations.
156	
157	METHODS
158	We conducted a systematic review of chikungunya CMGs using Cochrane systematic review
159	methodologies, ²⁰ structured according to the Preferred Reporting Items for Systematic Reviews and Meta-
160	Analyses (PRISMA) statement (supplementary file). ²¹ The protocol is registered with the International
161	Prospective Register of Systematic Reviews (PROSPERO) (CRD42020167361). ²²

162

163 Search strategy

164 We conducted an electronic database search for chikungunya CMGs using Ovid Medline, Ovid Embase,

165 Ovid Global Health, Scopus, Web of Science Core Collection and WHO Global Index Medicus from

166 inception to 14th October 2021. Search strategies applied the Canadian Agency for Drugs and

167 Technologies in Health (CADTH) database guidelines search filter (supplementary file 1).²³ Further

168	CMGs were identified through an extensive systematic grey literature search up to 16 th September 2021.
169	We searched Google and Google Scholar using predefined keywords in main languages including Arabic,
170	English, French, German, Mandarin, Russian, and Spanish. We also contacted clinician members of the
171	global International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) network
172	requesting CMGs. ²⁴
173	
174	Eligibility criteria
175	We included chikungunya CMGs that provided treatment and/or supportive care recommendations. There
176	was no language limitations We excluded CMGs that were pure diagnostics, animal, or public health
177	guidelines. Only the most recent version of any CMG was included.
178	
179	Screening and data extraction
180	Search results were screened independently by two reviewers using the Rayan systematic review
181	software. ²⁵ CMGs were screened first by title and abstract, then by full text. Screening, data extraction
182	and critical appraisal were completed by two reviewers. Data was extracted by one reviewer using a
183	standardised form and validated by a second reviewer (supplementary file). We extracted data on
184	bibliography, issuing organisations, populations covered, supportive care and treatment recommendations
185	for the acute and chronic disease (supplementary file). Disagreements were resolved via consensus or by a
186	third reviewer. Non-English language CMGs were screened, and data was translated using Google
187	translate and screened and data extracted by reviewers with good to excellent knowledge of the language.
188	
189	Quality appraisal
190	Quality was independently assessed by two reviewers using the Appraisal of Guidelines for Research and
191	Evaluation II (AGREE II) Instrument. ²⁶ This tool provides an objective framework which aims to assess
192	the guideline development process and quality. It is s a 23-item tool that spans six domains comprising
193	different aspects of the CMG: 1) scope and purpose; 2) stakeholder involvement; 3) rigour of

development; 4) clarity of presentation; 5) applicability and 6) editorial independence. Each domain has
several sub-criteria which are scored to assess whether the criteria are met using a seven-point Likert
scale, from 1 (strongly disagree) to 7 (strongly agree). A score of 100% is achieved if a CMG scores 7 for
all items in the domain and 0% if each reviewer scored 1 for all domain items. The final domain score
was calculated as the average score by the different reviewers, as per the AGREE-II tool's user manual.²⁶
When there was limited information about the methodology presented in the CMG, efforts were made to
search for additional information via associated webpages.

201

202 CMGs were considered of high quality if they scored more than 60% in three or more domains, including 203 domain three (rigour of development), which is considered a high-quality indicator; moderate quality if 204 they scored more than 60% in three or more domains but not in domain three and low quality if they did 205 not reach these criteria. As per AGREE-II methodology, individual CMGs were also given an overall 206 quality assessment score, which was informed by the domain scores, ranging from one to seven (high-207 quality score ≥ 6 ; medium-quality score 4-5; low-quality score ≤ 3), together with a recommendation for 208 use with or without further modifications.²⁶ CMGs with a total overall quality score of 1 were not 209 recommended for use, total overall scores of 2-5 were recommended for use with modifications and 6-7 210 recommended for use without modifications.

211

212 Data analysis

213 We conducted a narrative synthesis of the quality, availability, scope, and inclusivity of the CMGs. The

214 availability of CMGs was assessed by whether open-sourced CMGs could be identified and were

- stratified by origin: (1) international and regional organisations (e.g., WHO; PAHO); (2) national
- 216 organisations (e.g., Ministries of Health) and (3) clinical reference websites (e.g., Medscape, UptoDate).

217 We assessed inclusivity based on inclusion of recommendations for traditionally more vulnerable at-risk

218 groups, including infants/children, pregnant women, older people, and people living with HIV or

219	comorbidities that may render them at higher risk of severe disease. The ggplot2 library and Tableau
220	software were used to produce graphics. ^{27,28}
221	
222	Patient public involvement
223	There was no patient or public involvement due to the ongoing pandemic restrictions.
224	
225	RESULTS
226	From 2981 records screened, twenty-eight CMGs met the inclusion criteria (Figure 1). 9,29-54
227	
228	Figure 1: PRISMA diagram
229	
230	Characteristics of included CMGs
231	Half of the CMGs were in English (50%, 14/28); 9,30–32,34,36,37,42,44–47,52,54 43% (12/28) in Spanish 29,35,38–
232	41,43,48–50,53,55 and 7% (2/28) in Portuguese. ^{33,51} Most were produced by National Health Organisations
233	(61%, 17/28), and 46% (13/28) ^{32-34,36,37,39,44-46,51-54} published in the last 5 years (Table 1).
234	
235	Availability
236	Half of the CMGs were produced in Latin Americas (50%, 14/28), ^{29,33,35,38,40,41,43,48-51,53-55} 14% in Europe
237	(4/28), ^{9,30,31,39} 14% in Asia (4/28), ^{37,42,44,45} 11% in North America (3/28) ^{32,34,36} and 11% by global
238	organisations (3/28) ^{32,34,52} (Figure 2). Most were produced by organisations in high- or upper-middle
239	income countries (61%, 17/28), ^{33,35,38,40,41,48,49,51,54,55} followed by lower-middle-income countries (18%,
240	5/28). ^{29,37,43–45} None were produced in a low-income country. (World Bank) (Table 1). Sixty-four percent
241	(18/28) of CMGs were produced in countries where Chikungunya is endemic.
242	
243	
244	

Figure 2: Chikungunya outbreaks (1999-2020) and geographic distribution of identified CMGs

- 246
- 247 Quality
- 248 The overall quality of the CMGs ranged from one to seven (median: 2 out of 7) (Table 2). Most (86%,
- 24/28) were of low quality (score \leq 3), two of median (scores 4-5) and two of high quality (score 6-7).
- 250 The higher scoring CMGs were produced by Mexico Ministerio De Salud, UpToDate, World Health
- 251 Organisation Southeast Asia and República Dominicana Ministerio de Salud Pública. Although
- 252 UpToDate produces CMGs for unspecified settings, these are only accessible upon subscriptions. No
- 253 freely accessible, global, high-quality CMG was identified within our study. The highest scoring domains
- were clarity of presentation [median (IQR): 61% (58-72)] and scope and purpose [median (IQR): 56%
- 255 (43-70)]. The lowest scoring domain was editorial independence [median (IQR): 15% (0-35)]. Similarly,
- the domains for rigour of development [median (IQR): 28% (21-45)], applicability [median (IQR): 29%
- 257 (16-40)] and stakeholder involvement [median (IQR): 36.1 (2-63)] scored low. Broad variation in scores
- were seen in the domains for 'editorial independence' and 'rigour of development' especially (Table 1
- and Figure 3).
- 260

261

262 Table 1 AGREE II scores

263 The table present the results of the assessment of each Chikungunya clinical management guidelines

using the AGREE II scores by domain and the overall quality.

265

СМG	Year	Scope and purpose (%)	Stakeholder involvement (%)	Rigour of development (%)	Clarity of presentation (%)	Applicability (%)	Editorial Independence (%)	Overall quality (1-7)
ACCAR	2018	61.1	36.1	44.8	55.6	20.8	41.7	1

BCDC	2017	19.4	11.1	13.5	61.1	12.5	16.7	2
BMS	2015	47.2	27.8	18.8	72.2	27.1	16.7	1
BSR	2017	44.4	22.2	51	69.4	10.4	45.8	2
BZLMS	2017	55.6	30.6	28.1	58.3	45.8	0	1
CDC	2020	8.3	25	7.3	58.3	12.5	0	1
CMS	2018	69.4	19.4	24	69.4	39.6	0	2
CRMS	2014	47.2	30.6	8.3	50	50	0	1
DRMSP	2014	83.3	41.7	35.4	61.1	62.5	0	4
EMS	2014	58.3	30.6	20.8	66.7	52.1	0	2
ESMS	2014	77.8	38.9	26	69.4	29.2	12.5	3
GMS	2015	69.4	50	16.7	58.3	16.7	0	2
IMOH	2016	16.7	5.6	9.4	58.3	12.5	16.7	1
JIMA	2020	52.8	38.9	40.6	58.3	8.3	95.8	2
MMS	2015	94.4	63.9	93.8	91.7	62.5	87.5	7
MS	2019	8.3	44.4	36.5	58.3	4.2	41.7	1
РАНО	2011	52.8	47.2	22.9	52.8	31.3	25	1
PHE	2014	2.8	2.8	0	27.8	4.2	0	1
PMS	2015	80.6	44.4	36.5	83.3	29.2	0	3
PMSP	2015	75	44.4	27.1	47.2	41.7	0	2
PRMS	2014	27.8	13.9	27.1	72.2	31.3	0	2
PUK	2014	38.9	36.1	46.9	44.4	6.3	66.7	2
RSMBT	2020	55.6	33.3	22.9	24	72.2	22.9	2
SMOH	2016	72.2	38.9	31.3	63.9	29.2	0	3
SPILF	2015	55.6	38.9	45.8	61.1	16.7	33.3	2
UTD	2020	47.2	44.4	85.4	80.6	35.4	91.7	6
WHO	2017	69.4	33.3	43.8	55.6	37.5	25	2
WHOSEA	2008	80.6	61.1	52.1	88.9	22.9	0	4

Median		-	55.6	36.1	27.6	61.1	28.1	14.6	2
Rang	ge	-	(8-94)	(2-63)	(0-93)	(27-91)	(4-62)	(0-87)	(0-7)
266	·								
267	Abbr	eviations:	ACCAR: P	an-American Le	ague of Associat	ions for Rheumat	ology-Central A	merican Caribbean	
268	and A	Indean Rho	eumatology	Association, BC	DC: Bangladesh	Centre for Disea	se Control, BMS	: Bolivia Ministeri	0
269	De Sa	alud, BSR:	Brazilian S	ociety of Rheum	atology, BZLMS	Brasil Ministéri	o da Saúde, CDC	C: Centers for Disea	ase
270	Contr	ol and Pre	vention, CM	IS: Chile Minist	erio De Salud, C	RMS: Costa Rica	Ministerio De Sa	alud , DRMSP:	
271	Repúl	blica Dom	inicana Min	isterio de Salud	Pública, <i>EMS:</i> E	cuador Ministeric	De Salud, ESM	S: El Salvador	
272	Minis	sterio De S	alud, GMS:	Guatemala Min	isterio De Salud,	<i>IMOH:</i> India Mi	nistry of Health,	JIMA: Journal of	
273	India	n Medical	Association	. MMS: Mexico	Ministerio De Sa	ulud, <i>MS:</i> Medsca	pe, <i>PAHO:</i> Pan A	American Health	
274	Orgar	nisation, P	HE: Public	Health England,	PMS; Peru Mini	sterio De Salud, A	PMSP: Paraguay	Ministerio de Salu	ıd,
275	PRMS	S: Puerto F	Rico Ministe	erio De Salud, P	UK: Patient UK,	RSMBT: Revista	da Sociedade Br	asileira de Medicir	ie
276	Tropi	cal, SMOP	I: Spain Mi	nistry of Health,	SPILF: Société o	de Pathologie Info	ectieuse de Langu	ue Française, UTD	:
277	UptoI	Date, WHC	D: World He	ealth Organisatio	n, WHOSEA: Wo	orld Health Organ	nisation Southeas	at Asia, CMG: Clin	ical
278	mana	gement gu	idelines, AC	GREE- Appraisa	l of guidelines fo	r research and ev	aluation		
279 280 281 282	Figure 3 AGREE II domain scores								
283									
284	Inclu	ısivity							
285	Most	CMGs (8	89%, 25/28	9,29,31–35,37–42,44	4-53,55 mentioned	d vulnerable gro	oups including c	children (75%,	
286	21/28	8), ^{9,29,31,32}	,37–43,45,46,48-	-51,53,55 pregnan	t women (68%,	19/28), ^{9,29,32,33,3}	5,38–45,47–49,51,52,52	^{2,53} people aged >	>65
287	years	s (96% 27	/28), ^{9,29,31-5}	⁵⁵ people living	with HIV (21%	6, 6/28) ^{29,38,40,41,}	^{49,55} and people	living with	
288	como	orbidities	(61%, 17/2	28).9,29,31,32,34,36-	38,40,41,43,44,48–51,54	⁴ Many (61% (1	7/28) ^{30,31,33–37,41}	,42,44,45,45–47,53–55,55	,55
289	provi	ided some	guidance	for all of these	groups; howev	er, recommenda	tions varied in	their level of deta	ail
290	with	only a mi	nority givi	ng specific sup	portive care gu	idance for pregr	nant women and	l children.	
291									
292									

293 S	Scope
-------	-------

294	All CMGs gave recommendations for the management of acute and chronic manifestations of
295	chikungunya, although the level of detail varied (Table 2 and 3). There was considerable variation
296	between CMGs in the recommendations for the management of patients with long-term sequelae and for
297	different at-risk populations . Further, there were differences in the guidance addressing preventive
298	measures of disease transmission both in the community and in hospital settings.
299	
300	Acute Phase
301	Half of the CMGs (50%, 14/28) ^{9,29,37,40,41,43,45–47,51–55} stated that there was no efficacious antiviral treatment
302	available for CHIKV and most (96%, 27/28) that management should be symptom-driven. ^{29–38,40–55,55}
303	Many (68%, 19/28) ^{29,32,33,35,37,38,40-45,47-53} provided guidance on management of the acute phase, with
304	administration at different health facility levels depending on disease severity: outpatient care (home
305	based and at the primary care level), secondary level (district hospitals) and at the tertiary level (referral
306	hospitals). The principles of outpatient management were generally consistent amongst the CMGs with
307	recommendations including rest (39%, 11/28), ^{32,32,33,36,38,40,46-48,52,53,55} hydration (43%, 12/28), ^{29,31-33,36-}
308	^{38,41,46,52,53,55} cold compresses (11%, 3/28), ^{38,45,51} antihistamines (39%, 11/28) ^{32,38,40,42,44,45,49,53-55} and
309	analgesia (96% 27/28). A minority (25%, 4/12) ^{29,37,38,52,53} advised the need to assess the patient's
310	hydration status to assess whether intravenous fluid was required, one (8%, 1/12) ⁵³ advised suspending
311	diuretics.
312	
313	Fifty-four percent of CMGs (15/28) ^{33,35,37,38,40-45,47-49,51,52} recommended hospitalisation for severe cases;

however, only a minority $(39\%, 11/28)^{9,29,33,34,37,38,41,46,51,52,54}$ gave guidance regarding the clinical

315 management of severe cases. The CMGs $(54\%, 15/28)^{33,35,37,38,40-45,47-49,51,52}$ providing guidance regarding

316 hospitalisation criteria gave several indications including: any signs of haemodynamic instability (46%,

317 13/28), ^{33,35,38,41,45,47,49,51,52} or atypical chikungunya (36%, 10/28),^{29,33,35,38,41,43,47,49,52} severe pain

318 unresponsive to analgesia (25%, 7/28),^{35,37,38,41,42,44,45} signs of haemorrhage (46%, 13/28)^{29,33,35,38,41-45,47-49}

319 and signs of decompensation from underlying comorbidities (25%, 7/28).^{29,33,35,38,43,47,49} Supportive care recommendations included use of intravenous fluids to treat shock (55%, 6/11),^{29,37,45,45,47,48,52} 320 haemodynamic monitoring (55%, 6/11),^{29,33,34,45-47} blood components (18%, 2/11), ^{37,45} intensive care 321 322 support as required $(9\%, 1/11)^9$ and immunoglobulins in chikungunya-related polyneuropathy (4%, 1/28). 323 324 Antimalarials 325 None of the CMGs advocated for use of empiric antimalarials, despite some CMGs $(10\%, 2/21)^{9.44}$ 326 advising malaria should be considered in the differential diagnosis. However, CMGs did discuss the use 327 of antimalarial chloroquine derivatives for the treatment of chronic manifestations (24%, 4/17).^{33,37,44,45} 328 329 Analgesia 330 All CMGs recommended some form of analgesia with 75% (21/28)^{29,31–33,35,37,40–48,52–55,55} recommending 331 paracetamol as first line treatment for pain and its antipyretic properties. Some (36%, 10/28)^{9,33,35,40,47,48,52-} 332 ⁵⁵ advised escalating to opiates, tramadol, or codeine alone or in combination with paracetamol, for 333 uncontrolled pain. Two (7%, 2/28)^{33,51} recommended dipyrone for mild pain. There was wide and 334 contradictory advice given regarding non-steroidal anti-inflammatory drugs (NSAIDs) in the acute phase. Half (54%, 15/28) advised considering the use of NSAIDs.^{29,31,32,34,36-42,44,47,48,55} However, 75% (21/28) 335 advised avoiding salicylates in adults during the acute phase due to risk of haemorrhage, 9,29,32-35,37-44,47-53 336 and 40% (11/28) advised against NSAIDs, 9,33,35,43,45,46,49,51-54 while one CMG stated that NSAIDs should 337 338 not be avoided, citing a lack of evidence.³² Some (29%, 8/28)^{9,29,35,41,46,48-50} recommended excluding co-339 infection with dengue prior to NSAID administration. 340 341 *Corticosteroids* The recommendations for corticosteroids were also heterogenous. A third (36%, 10/28)^{32,35,41,44,46-48,50,53,54} 342 343 advised a short course of corticosteroids if not responding to analgesia. A number of indications were 344 given for corticosteroid, including severe joint pain refractory to NSAIDs or other analgesia (80%,

345	8/10); ^{32,35,41,44,46–48,53} highly inflammatory forms (30%, 3/10); ^{32,53,54} disabling arthritis (40%, 4/10) ^{32,41,44,54}
346	or when contraindications against NSAIDs (10%, 1/10).53 Prednisolone was most recommended (50%,
347	5/10), ^{32,41,46,53,54} with CMGs advising adult dosage ranging from 10mg to 20mg per day (60%, 3/5) based
348	on clinical judgment, ^{32,46,53} escalating to 0.5mg/kg/day (80%, 4/5) ^{32,41,53,54} for severe cases. Four CMGs
349	$(80\%, 4/5)^{32,41,53,54}$ gave corticosteroid duration advise, ranging, from 5 days $(60\%, 3/5)^{32,41,53}$ with a
350	weaning period of 10 days to 1-2 months for severe cases $(40\%, 2/5)^{32,54}$ with a correspondingly longer
351	weaning period. In contrast, two CMGs (40%, 2/5) stated that the duration of corticosteroid use should
352	not exceed one month, ^{32,53} with one citing the SPILF guideline. ⁹ Although the majority $(80\%, 4/5)^{32,41,53,54}$
353	advised on the need for tapering steroid doses, only one CMG gave a justification, stating that there was a
354	risk of rebound symptoms if abruptly withdrawn.54 The remaining CMGs (50%, 5/10) did not specify
355	corticosteroid dose or type. ^{35,44,47,48,50} In contrast to these recommendations, 43%
356	(12/28) ^{9,29,34,37,38,40,43,45,49,51,52,55} advised against the use of steroids in the acute phase. Only a minority gave
357	justifications for avoidance, stating either a lack of evidence (8%, 1/12), ³⁴ lack of short-or long-term
358	benefit regardless of form of administration (8%, 1/12) ⁵² or a risk of rebound symptoms (8%, 1/12). ⁵⁵
359	Furthermore, one CMG [cite] had contradictory recommendations within its guideline, advising the use of
360	short-term corticosteroids for individuals with refractory pain in the acute phase, while also advising
361	against the use of systemic corticosteroids in the acute phase. ²⁹
362	
363	A minority of CMGs (14%, 4/28) ^{29,32,33,54} also indicated the use of steroids in the subacute phase to treat
364	symptoms refractory to NSAIDs, moderate pain and for arthritis/tenosynovitis. Three of these CMGs
365	$(75\%, 3/4)^{32,33,54}$ advised that prednisolone was first-line, and that steroids use should be limited to one
366	month. One CMG $(25\%, 1/4)^{33}$ provided recommendations on how to assess improvement (ability to walk
367	without assistance; satisfactory pain control) to guide dose and duration.

371 Table 2 Summary of CMG treatment recommendations in the acute phase

- 372 The table presents an overview of the main treatments recommended in the acute phase in each guideline,
- and if a treatment was recommended to use, not recommended or if no advice was provided.
- 374 R= recommended. RA= recommended to avoid. NS= not stated.
- 375 *Indicated in subacute CHIKV
- 376

Guidelines	Region	Year	Acute interventions					
			Paracetamol	NSAIDs	Opioids	Antihistamines	Antimalarials	Steroids
ACCAR	Global	2018	R	RA	RA	NS	NS	R
BCDC	Asia	2017	R	RA	R	R	NS	RA
BMS	Latin America	2015	R	R	NS	NS	NS	RA*
BSR	Latin America	2017	R	RA	R	NS	NS	RA
BZLMS	Latin America	2017	R	RA	R	NS	NS	R*
CDC	North America	2020	NS	R	NS	NS	NS	NS
CMS	Latin America	2018	R	RA	R	R	NS	R
CRMS	Latin America	2014	R	RA	R	NS	NS	R
DRMSP	Latin America	2014	R	R	NS	R	NS	RA
EMS	Latin America	2014	R	R	R	NS	NS	R

ESMS	Latin America	2014	R	RA	R	NS	NS	RA
GMS	Latin America	2015	R	R	NS	R	NS	RA
ІМОН	Asia	2016	R	R	R	R	NS	R
JIMA	Asia	2020	R	R	NS	R	NS	RA
MMS	Latin America	2015	R	RA	NS	R	NS	RA
MS	North America	2019	NS	R	NS	NS	NS	RA
РАНО	Latin America	2011	NS	R	R	NS	NS	R
PHE	Europe	2014	NS	NS	NS	NS	NS	NS
PMS	Latin America	2015	R	R	NS	R	NS	RA
PMSP	Latin America	2015	R	R	R	NS	NS	R
PRMS	Latin America	2014	R	NS	R	NS	NS	R
PUK	Europe	2014	R	R	NS	NS	NS	NS
RSMBT	Latin America	2020	R	RA	R	NS	NS	R*
SMOH	Europe	2016	R	R*	R	NS	NS	NS
SPILF	Europe	2015	NS	RA	NR	NS	NS	RA
UTD	Global	2020	R	R	R	NS	NS	R*
WHO	Global	2017	R	RA	R	NS	NS	RA
WHOSEA	Asia	2008	R	R	NS	R	NS	NS

,	Total Recommended (R) % (n/n)	82% (23/28)	54% (15/28)	54% (15/28)	32% (9/28)	0% (0/28)	46% (13/28)			
,	Total Not Recommended (R) % (n/n)	0% (0/28)	39% (11/28)	4% (1/28)	0% (0/28)	0% (0/28)	43% (12/28)			
37 378 379	7 8 9 Abbreviations : NSAID: Non-s	steroidal Anti-in	flammatory Drug	gs, <i>WHOSEA</i> Wo	rld Health Organis	ation Southeast				
38(0 Asia, <i>PAHO</i> Pan American Hea	lth Organisation	, <i>EMS</i> Ecuador 1	Ministerio De Sal	ud, <i>ESMS</i> El Salva	ador Ministerio				
38 ⁻	1 De Salud, <i>PHE</i> Public Health E	ngland, <i>PRMS</i> P	Puerto Rico Minis	sterio De Salud, <i>l</i>	DRMSP República	Dominicana				
382	2 Ministerio de Salud Pública, <i>Ck</i>	MS Costa Rica	Ministerio De Sa	alud, PUK Patien	t UK, <i>BMS</i> Bolivia	Ministerio De				
383	3 Salud, <i>GMS</i> Guatemala Ministe	rio De Salud, Pl	MS Peru Minister	rio De Salud, SPI	LF Société de Path	nologie				
384	4 Infectieuse de Langue Française	Infectieuse de Langue Française, MMS Mexico Ministerio De Salud, PMSP Paraguay Ministerio de Salud, SMOH								
38	5 Spain Ministry of Health, <i>IMOF</i>	HIndia Ministry	of Health, BSR	Brazilian Society	of Rheumatology,	WHO				
386	6 WorldHealth Organisation, <i>BZL</i>	WorldHealth Organisation, BZLMS Brasil Ministério da Saúde, BCDC Bangladesh Centre for Disease Control, CMS								
387	7 Chile Ministerio De Salud, ACC	CAR Pan-Americ	an League of As	sociations for Rh	eumatology-Centr	al American				
388	8 Caribbean and Andean Rheuma	tologyAssociation	on, MS Medscap	e, CDC Centers f	or Disease Control	and Prevention,				
389	9 <i>RSMBT</i> Revista da Sociedade B	rasileira de Mec	licine Tropical, U	UTD UptoDate, J	IMA Journal of Ind	lian Medical				
39(0 Association.									
39 [.]	1									
392	2									
393	3 Chronic Phase									
394	4 Most CMGs (93%, 26/28) ^{9,29}	,32-55 addressed	I the manageme	ent of long-term	sequelae, based	on the				
39	5 principles of managing more	common infla	mmatory arthro	pathies such as	rheumatoid arth	ritis (RA). The				
396	6 recommendations included as	nalgesia, cortic	costeroids, disea	ase modifying a	nti-rheumatic dru	ugs (DMARDs)				
397	7 and antimalarial chloroquine	derivatives. So	ome CMGs (18	%, 5/28) ^{9,33,42,51}	⁵⁴ advised using	quantitative				
398	8 scoring measures (visual scal	les, clinical sco	ores and structu	red questionnai	res) to measure o	utcomes such				
399	9 as pain, joint involvement, qu	uality of life an	d functional ca	pacity in adults	. The most comm	non scale				
40(0 recommended to assess sever	rity and to mor	itor the efficac	y of treatment v	vas a visual analo	ogue scale				

- 401 (VAS) (80%, 4/5).^{9,33,51,54} Other scales recommended were Routine Assessment of Patient Index Data 3
- 402 (RAPID3), Disease Activity Score-28 (DAS28) and Douleur Neuropathique 4 (DN4) to assess the
- 403 functional impact of pain and level of neuropathic pain, respectively.^{9,54}
- 404
- 405 Analgesia
- 406 Most CMGs $(86\%, 24/28)^{9,29-33,35,36,39-44,46-54}$ advised managing chronic pain using analgesia, primarily
- 407 NSAIDs (75%, 18/24), ^{9,29,32,33,35,41-44,46-50,50-52,54} paracetamol (45%, 11/24)^{9,31-33,35,39,40,42,49,52,54} and opiates
- 408 (21%, 5/24).^{9,33,51,52,54} A minority $(13\%, 3/24)^{51,53,54}$ gave guidance regarding the duration of treatment
- 409 which ranged from reassessing after four, ⁵¹ eight⁵⁴ to several weeks.⁵³ The rest (92%, 22/24) lacked
- 410 clarity regarding the length of time analgesia should be continued.^{9,29,29–33,35,36,38,39,39–44,46–49,49,50,50,52}
- 411
- 412
- 413
- 414 *Corticosteroids*

415 Almost half the CMGs (46%, 13/28) advised giving steroids in the chronic phase.^{29,32,36,37,39,41-44,47,51,52} The

- 416 most common indication given for administration of corticosteroids was disabling peripheral arthritis
- 417 refractory to other treatments (62%, 8/13), 29,33,36,39,41,44,47,52 followed by neuropathic symptoms (8%,
- 418 1/13).⁵¹ Moreover, to those who experience arthralgia, arthritis, tendinitis, or bursitis with evidence of
- 419 severe synovitis, joint swelling and persistent elevation of inflammatory markers (8%, 1/13).³² Most
- 420 recommended prednisolone (31%, 4/13), 32,33,41,51 most (75%, 3/4) specifying a dosage of

421 0.5mg/kg/day.^{32,33,41} There was considerable variation in the recommendations regarding duration, with

- 422 CMGs advising courses of five,³² ten,⁴¹ 21,³³ or 28 days.³⁷ One CMG (8%) advised using 5 to 20 mg/day
- 423 prednisone for musculoskeletal and neuropathic symptoms for 6 to 8 weeks with a weaning period to
- 424 avoid symptom recurrence.⁵¹ For administration, although most CMGs advised oral steroids (31%,
- 425 4/13, 33,37,39,51 a few advised that local intra-articular injections could be used (15%, 2/13). 39,47 A minority
- 426 of CMGs $(18\%, 5/28)^{9,34,38,49,55}$ advised against the use of corticosteroids in the chronic phase giving

reasons such as the risk of rebound symptoms (20%, 1/5)⁵⁵ and lack of published evidence (20%, 1/5).³⁴
The rest of the CMGs did not give a justification for avoidance (60%, 3/5).^{9,38,49}

429

430 DMARDs

431 Over half of the CMGs (61%, 17/28)^{9,29,32,33,37,39,41,43–48,51–54} gave guidance on the use of DMARDs in the 432 chronic phase; yet there was variation on which DMARD was first line. Methotrexate was recommended as first line therapy by most (65%, 11/17);^{9,29,32,39,41,43,46–48,52,53} whereas others (24%, 4/17) recommended 433 434 chloroquine/ hydroxychloroquine.^{33,44,44,45} One (6%, 1/17) recommended that methotrexate should be used 435 for inflammatory joint disease (moderate or severe disease affecting >5 joints) and hydroxychloroquine reserved for less severe forms.⁵⁴ Another (6%, 1/17) noted that there was a lack of data comparing the 436 437 efficacy of methotrexate and hydroxychloroquine, but recommended hydroxychloroquine as it the safer 438 choice for its anti-inflammatory and possible antiviral effects.³³ Two CMGs (12%, 2/17) recommended 439 methotrexate either in combination with another DMARD, such as sulfasalazine or chloroquine.^{46,51} One 440 CMG (6%, 1/17) divided chronic manifestations into post-chikungunya rheumatoid arthritis 441 (methotrexate first line), post-chikungunya spondyloarthritis (NSAIDS first line) and post-chikungunya 442 undifferentiated polyarthritis (NSAIDs first line; corticosteroids second line).⁹ Five CMGs (18%) 443 provided guidance for neuropathic pain management of using amitriptyline, pregabalin, gabapentin and carbamazepine.9,33,45,51,54 444

445

446 Table 3 Summary of CMG recommendations for treatment of chronic sequalae

447 The table presents an overview of the main treatments recommended in the chronic phase in each

448 guideline, and if a treatment was recommended to use, not recommended or if no advice was provided.

449 R= recommended. RA= recommended to avoid. NS= not stated.

450

451

Guidelines	Region	Year		Analgesia			DMARDs	
			Paracetam ol	NSAIDs	Opioids	Steroids	МТХ	НСQ
ACCAR	Global	2018	NS	R	NS	NS	R	R
BCDC	Asia	2017	NS	NS	NS	NS	NS	R
BMS	Latin America	2015	NS	R	NS	R	R	NS
BSR	Latin America	2017	NS	R	R	R	R	R
BZLMS	Latin America	2017	R	R	R	R	NS	R
CDC	North America	2018	NS	R	NS	R	NS	NS
CMS	Latin America	2018	R	R	R	NS	R	NS
CRMS	Latin America	2014	R	R	NS	R	NS	NS
DRMSP	Latin America	2014	NS	NS	NS	RA	NS	NS
EMS	Latin America	2014	NS	R	NS	R	R	NS
ESMS	Latin America	2014	NS	R	NS	R	R	NS

GMS	Latin America	2015	NS	NS	NS	RA	NS	NS
ІМОН	Asia	2016	NS	R	NS	NS	NS	R
JIMA	Asia	2020	NS	NS	NS	R	NS	R
MMS	Latin America	2015	R	R	NS	RA	NS	NS
MS	North America	2019	NS	NS	NS	RA	NS	NS
РАНО	Latin America	2011	NS	R	NS	R	R	RA
РНЕ	Europe	2014	NS	NS	NS	NS	NS	NS
PMS	Latin America	2015	R	NS	NS	NS	NS	NS
PMSP	Latin America	2015	NS	R	NS	R	R	NS
PRMS	Latin America	2014	NS	R	NS	NS	NS	NS
PUK	Europe	2014	R	NS	NS	NS	NS	NS
RSMBT	Latin America	2020	R	R	R	NS	R	R
SMOH	Europe	2016	R	NS	NS	R	R	NS
SPILF	Europe	2015	R	R	R	RA	R	NS
UTD	Global	2020	R	R	NS	R	R	RA
WHO	Global	2017	R	R	R	NS	R	NS
WHOSEA	Asia	2008	R	R	NS	R	NS	NS
Total Recommended (R) % (n/N)		39% (11/28)	64% (18/28)	18% (5/28)	46% (13/28)	65% (11/17)	41% (7/17)	

Total Not Recommended (R) % (n/N)	0% (0/28)	0% (0/28)	0% (0/28)	18% (5/28)	0% (0/28)	7% (2/28)

452 453 Abbreviations: NSAID: Non-steroidal Anti-inflammatory Drugs, DMARD: Disease-modifying Antirheumatic 454 Drugs; MTX: Methotrexate; HCQ: Hydroxychloroquine; WHOSEA World Health Organisation Southeast Asia, 455 PAHO Pan American Health Organisation, EMS Ecuador Ministerio De Salud, ESMS El Salvador Ministerio De 456 Salud, PHE Public Health England, PRMS Puerto Rico Ministerio De Salud, DRMSP República Dominicana 457 Ministerio de Salud Pública, CRMS Costa Rica Ministerio De Salud, PUK Patient UK, BMS Bolivia Ministerio De 458 Salud, GMS Guatemala Ministerio De Salud, PMS Peru Ministerio De Salud, SPILF Société de Pathologie 459 Infectieuse de Langue Française, MMS Mexico Ministerio De Salud, PMSP Paraguay Ministerio de Salud, SMOH 460 Spain Ministry of Health, IMOH India Ministry of Health, BSR Brazilian Society of Rheumatology, WHO World 461 Health Organisation, BZLMS Brasil Ministério da Saúde, BCDC Bangladesh Centre for Disease Control, CMS Chile 462 Ministerio De Salud, ACCAR Pan-American League of Associations for Rheumatology-Central American 463 Caribbean and Andean Rheumatology Association, CDC Centers for Disease Control and Prevention, MS 464 Medscape, RSMBT Revista da Sociedade Brasileira de Medicine Tropical, UTD UptoDate, JIMA Journal of Indian 465 Medical Association.

466

467 Vulnerable populations

468 Pregnant women

469 Most (75%, 21/28) addressed management during pregnancy. $^{9,29,31-33,35,36,38-45,47-49,51-53}$ Yet, limited CMGs

470 (29%, 6/21) ^{9,38,41,43,52,53} gave guidance on CHIKV symptom control during pregnancy, advising to use

471 paracetamol (67%, 4/6).^{9,38,52,53} Moreover, to consider amoxicillin in febrile (>38.5C) women (17%, 1/6) ⁹

472 and to avoid NSAIDs and aspirin (50%, 3/6) ^{9,52,53} due to the risks of closure of the ductus arteriosus, fetal

- 473 renal failure and risk of intrauterine death [cite]. Some CMGs (57%, 12/21) recommended referral to
- 474 health services for monitoring of mother and child, but the advice varied.^{9,29,35,38,40,40–42,47–49,51,52} One (8%,
- 475 1/12)³⁵ recommended admitting all pregnant women with suspected chikungunya if in the last trimester;

476	whereas one (8%, $1/12$) specified from 38 weeks. ⁴⁸ In contrast, two CMGs (16%, $2/12$) ^{33,49}
477	recommended daily monitoring of pregnant women with suspected chikungunya; three (25%, 3/12)
478	recommended obstetric referral if in the final trimester. ^{9,52,53} Delaying delivery beyond the highly
479	viraemic stage to try to prevent mother-to-child transmission (MTCT) was advised in four (33%, 4/12).
480	One (8%, 1/12) ⁹ advising use of tocolytics, one (8%, 1/12) ³⁵ postponement of elective caesarean section.
481	Further, four CMGs (19%, 4/21) advised that caesarean sections did not prevent mother-to-child
482	transmission (MTCT). ^{9,38,45,49}
483	
484	Children
485	Most CMGs (79%, 22/28) identified children and neonates as having a higher risk of developing severe
486	CHIKV infection and advised hospital referral, but their criteria varied. ^{9,29,31,33,35,37-40,40-55} Four (18%,
487	4/22) 9,41,52,53 advised inpatient monitoring for signs of infection of neonates born to mothers with
488	suspected chikungunya for seven days. The guidance changed for neonates born to mothers with
489	confirmed infection, with three CMGs (14%, 3/22) advising that inpatient monitoring should be five days,
490	^{9,52,53} one at least seven days. ⁴¹ One (5%, 1/22) recommended that symptomatic neonates should be
491	managed in the neonatal intensive care unit. ³⁸ Four_(18%, 4/22) addressed breastfeeding, stating there was
492	no risk of transmission through breastmilk. ^{38,44,45,47} Four CMGs (18%, 4/22) advised infants at risk of
493	CHIKV infection younger than 12 months to be admitted to hospital for observation. ^{29,37,40,45} Four (18%,
494	4/22) advised children under two years old to be followed up daily in a primary care facility during the
495	acute phase [cite]. Nine CMGs (32%) specified the risk of Reye's syndrome associated with aspirin use in
496	children younger than 12 years old [cite]. Four (18%, 4/22) ^{9,29,52,53} advised against NSAID administration
497	in children under the age of 3 months, and three (11%) against codeine use in children younger than 12
498	years. ^{9,52,53} One CMG (4%) advised against use of dipyrone in infants younger than three months or
499	weighing less than 5kg. ⁵⁴
500	

501

502 *Older adults and those with comorbidities*

503 Although 96% (27/28) of CMGs^{9,29,30,32,34–51,53–56} included advice for older adults (CMGs generally 504 defined as those aged over 60 or 65 years) and those with comorbidities, this advice was limited in scope. 505 Two (22%, 2/9) stated that people over 60 years old had a 50-times higher mortality risk compared to younger adults.^{41,43} While 81% (22/27)^{9,29,31,32,35–39,41,42,44,46–53,55} advised that older adults were at increased 506 507 risk of severe/atypical disease and death, only seven (26%, 7/27)^{37,41,41,42,45,48,53} recommended referral to 508 hospital for monitoring. One CMG (11%, 1/9) stated that in people over 65 years old CHIKV infection 509 could cause complications and lead to dementia, paralysis and kidney disease.⁴⁴ Over half of the CMGs 510 $(61\%, 17/28)^{9,29,31,32,34,36,38,40,43,44,48-52,54}$ advised that people with chronic conditions such as diabetes, 511 hypertension or heart disease were at higher risk of developing severe/ atypical disease or deterioration 512 due to decompensation of their pre-existing condition. Of these, nine (81%, 9/11) suggested having a 513 lower threshold for hospital referral, and three close monitoring of these patients, and adult over 65 years 514 old. In keeping with general guidance, five CMGs (45%, 5/11) advised prescribing NSAIDs with caution 515 in patients with comorbidities due to risk of renal impairment and bleeding risk. 33,38,40,48,54

516

517 Prevention of onward transmission

518 Most CMGs (71%, 20/28)^{9,29,31,32,35,37,38,40–51,53} gave advice regarding prevention of transmission.

519 Recommendations included the use of mosquito repellents (50%, 10/20),^{9,31,35,40,41,43,44,47,50,51} protective

520 clothing (35%, 7/20), 31,40,41,43,50,51 mosquito nets (60%, 12/20), $^{9,37,40-44,47,49-51,53}$ and isolation (25%, 5/20)

521 of the patient and those in proximity to the patient. It was recommended to continue these measures

522 throughout the febrile phase of illness to reduce risk of transmission. In contrast, two CMGs stated that

- 523 there was no requirement to segregate the infected patient in a household.^{44,45} Only three CMGs (15%,
- 524 3/20) advised on the risk of blood-borne transmission^{9,38,46} with one specifying highest risk within the first

525 five days of symptomatic infection.³⁸ Two (10%, 2/20) highlighted risk of transmission via organ/tissue

526 transplantation.^{38,46} Seven CMGs (35%)^{9,29,44,45,48,50,51} recommended vector control measures around the

hospital/homes of infected patients, using insecticides,^{9,48} fumigation²⁹ and eradication of breeding
sites.^{9,50} Some (65%, 13/20) advised informing public health authorities. ^{29,31,31,35,40–42,44,45,47,48,48–50}

530 Discussion

531 This review highlights the limited availability of high-quality CMGs for chikungunya globally. In the 532 CMGs identified there were heterogenous recommendations on supportive care and treatments. Although 533 there was a consensus in the guidelines on the symptomatic treatment for acute non-severe illness, there 534 was a general lack of detailed supportive care guidance regarding patients with acute severe disease. 535 Furthermore, there were significant differences in the guidance around corticosteroids, with certain CMGs 536 advocating for their use in the acute phase, while a third advised that the acute phase was a 537 contraindication. The duration of steroid treatment for both acute and chronic disease was another point of 538 contention between the CMGs. The evidence base around corticosteroid use in acute illness is uncertain 539 with studies limited in size and a scarcity of RCTs investigating corticosteroid use in acute CHIKV. 540 541 The evidence base around corticosteroid use in acute CHIKV is uncertain. One prospective randomized 542 parallel group study of 120 patients with acute CHIKV in South India demonstrated that the addition of 543 corticosteroid to NSAIDs reduced pain and improved quality of life and advocated for combination 544 treatment in acute illness.⁵⁷ Another small study of 19 cases observed an improvement in mobility with 545 short term corticosteroids in acute CHIKV, however noted that there was a risk of rebound symptoms

546 after treatment cessation.⁵⁸ Several reviews advised against the use of corticosteroids citing risks such as

547 rebound symptoms and immunosuppression causing potential disease exacerbation.^{59,60} It can be

reasonably assumed that the clinical guidelines are contradictory and lack clarity due to a scarcity of

research into the use of corticosteroids in acute chikungunya infection.

550

The joint pain caused by CHIKV infection may be debilitating, which can limit even the simplest daily
activities. Polyarthralgia is recurrent in 30 to 40% of infected individuals and may persist for years.⁶¹

27

Furthermore, CHIKV infection can lead to death either through the infection and its associated
complications or by triggering a decompensation in patients with pre-existing co-morbidities.⁶² The risk
of prolonged sequelae in populations in lower resourced settings especially can have a profound impact
on livelihoods, with a wider socio-economic impact on individuals, their families and the wider society.
Considering the high number of people affected and at risk of CHIKV infection, the scarcity and
heterogeneity as well as the sometimes contradictory treatment recommendations in the CMGs available
for chikungunya are reasons for concern.

560

561 Most CMGs included guidance on the treatment for pregnant women and children and there was general 562 consensus that this group were at higher risk of severe infection. Yet, guidance regarding symptomatic 563 treatment was limited and there were variations in the guidance around referral criteria to health services. 564 Moreover, there were wide variations in risk and need for monitoring of infection in young children, and 565 in the treatment recommendations and duration. Furthermore, only a minority of CMGs mentioned 566 potential factors to mitigate the risks of MTCT during delivery. For children, although many CMGs 567 identified that they were a high-risk group, only a minority gave guidance on hospitalisation criteria and 568 advised on symptom control. The CMGs were also limited in specific advice for older people and for 569 those with co-morbidities, both of whom are at higher risk of more severe disease. Given the substantial 570 risk CHIKV infection presents to neonates, the lack of clear guidance around reducing MTCT is a 571 concern. Although there are novel approaches to prevent the risk of MTCT, such as anti-CHIKV 572 hyperimmunoglobulins, there is currently no approved treatment ^{63–65} and published studies are scarce. 573

Furthermore, there was considerable variation in the guidance for treating and managing long-term
chronic, often debilitating, sequelae. The evidence into effective treatments is limited, and symptomatic
treatment without appropriate individual follow-up, whilst crucial to the quality of life of many patients,
has not been found to have an effect in diminishing mortality.⁶⁶ A systematic review of five RCTs with

28

small sample sizes found that the evidence on treatments was insufficient from a safety or efficacy point
of view.⁶⁷

580

581 Although most CMGs provided recommendations for post-acute follow-up care and treatment of chronic 582 complications, the recommendations were heterogenous and with limited evidence provided to support 583 them. There was variation in the recommendations of DMARDs for the management of chronic 584 chikungunya, particularly between hydroxychloroquine and methotrexate. One study examined 585 combination DMARD therapy versus hydroxychloroquine treatment in 72 patients with post-chikungunya 586 arthritis and found that a combination of DMARDs were superior to hydroxychloroquine monotherapy 587 treatment with improvements in disability, reduction in pain and disease activity.⁶⁸ Despite 588 acknowledging this lack of benefit, however four CMGs recommended hydroxychloroquine as a first line 589 DMARD.^{33,37,44,45} Existing interventional clinical research studies are limited in size as highlighted in 590 Martí-Carvaial et al., with a lack of standardised methodologies, the ability to conduct meta-analyses is 591 restricted, thus limiting our evidence base in determining the most effective therapies for treating chronic 592 manifestations of CHIKV infection.⁶⁷ The paucity of clear guidance is a disservice to patients, particularly 593 given that most patients developing acute severe illness and complications fall within vulnerable groups. 594 Our data highlights a need for robust RCTs with adequate statistical power to identify best supportive care 595 and new treatments to improve short and long term CHIKV outcomes.

596

This review is not without limitations. Despite a systematic search, additional local guidelines not retrieved by our searches may exist. Approximately half of the included CMGs were in a language other than English, and although these were assessed by a reviewer with good knowledge of that language, there may have been slight nuances lost in translation. Furthermore, the AGREE-II tool ²⁶ assess methodological aspects relevant to guideline development, but not the validity of the clinical management recommendations themselves. Whilst many of the CMGs scored poorly in the rigour of development domain, conclusions about the validity of the clinical guidance made can therefore not be derived from these scores.²⁶ Despite

604 these limitations, this review identifies concerning gaps and disparities within the CMGs. Firstly, there is 605 an issue of accessibility with the two highest quality CMGs identified in this review not being freely 606 available. One is only available via paid subscription⁶⁹ and the other a national guideline in Spanish.⁴⁹ 607 Developing CMGs is resource intensive, and for infectious diseases with rapidly changing epidemiology, 608 requires systems for regular reviews of the literature, updating and re-dissemination. CHIKV 609 disproportionally impacts on lower resourced settings, where such resources may not be readily available. 610 Further, other infections may take priority when there is international pressure and/or funding to develop 611 research and guidelines (e.g., SARS-CoV-2, HIV, malaria). International high-quality CMGs can fill this 612 gap, if they are readily accessible, and can easily by adapted and adopted by local settings during outbreaks. 613 This may also help ensure there are resources available to incorporate new evidence and disseminated this 614 via international platforms. The WHO new living Covid-19 review is an example of this.

615

616 Conclusion

617 There is a lack of high-quality CMGs detailing supportive care guidance in chikungunya globally. 618 particularly for those at risk of severe illness. Given the risks that CHIKV infection pose globally and in 619 particular to vulnerable groups such as children, individuals older than 65 years and those with co-620 morbidities, it is essential that existing guidelines are updated and adapted to include recommendations 621 for people with severe illness. Chikungunya is an illness predominantly affecting populations in lower-622 resourced settings, with profound impact on quality of life and livelihoods. Further research is needed into 623 effective treatments and vaccines, to generate evidence to inform high quality CMGs and improve patient 624 and epidemic outcomes. Investment in a 'living review' framework, for international CMGs that can be 625 readily adopted by local settings is recommended to improve access to inclusive, up to date, evidence-626 based treatment guidelines.

627

628

629 Author's contributions

- AD, VC, LS, SL, EH, STJ, EW, MM, IR developed the study protocol. EH, AD carried out the database
- 631 search with input from MM, EW and IR. EW, MM, IR, AD, EC conducted the grey literature search.
- 632 EW, RJ, AD, MM screened articles for inclusion. AD, EW, IR, RJ, MM extracted the data and completed
- 633 the risk of bias analysis. EW, MM, RJ, SL, and IR led on data analysis and presentation of the results. All
- 634 co-authors informed the interpretation of the findings. EW led on writing the manuscript with inputs from
- 635 LS, IR, MM, DD, RN, PPJ, ES and KG. LS, PH, TF, LB and STJ provided overall supervision,
- 636 leadership and advice. PH, HG, STJ, TF, PWH, LS, AD, and LB conceptualised the project. All authors
- 637 reviewed and approved the final version of the manuscript.
- 638

639 Acknowledgements

- 640 Thanks to the ISARIC Global Support Centre for logistical and administrative support, especially to Sarah
- 641 Moore and Romans Matulevics for invaluable support for this project.
- 642

643 Funding statement

644 This work was supported by the UK Foreign, Commonwealth and Development Office, Wellcome Trust

645 [215091/Z/18/Z], the Bill & Melinda Gates Foundation [OPP1209135]. For the purpose of Open Access,

- the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising
- 647 from this submission.
- 648

649 Competing interests

- All authors have completed the ICMJE uniform disclosure form and declare: no support from any
- organisation for the submitted work; no financial relationships with any organisations that might have an
- 652 interest in the submitted work in the previous three years.
- 653

654 Ethical approval

655 Not required

656

- 657 Data sharing
- 658 All of the data is presented in the manuscript and supplementary material.

659

660 Transparency statement

- 661 The lead author (the manuscript's guarantor) affirms that the manuscript is an honest, accurate,
- and transparent account of the study being reported; that no important aspects of the study have
- been omitted; and that any discrepancies from the study as originally planned and registered have
- been e
- 665 xplained.

666 List of abbreviations:

- 667 CHIKV- Chikungunya Virus
- 668 CMG- Clinical Management Guideline
- 669 DMARD- Disease Modifying Anti-Rheumatic Drug
- 670 PAHO- Pan American Health Organisation
- 671 WHO- World Health Organisation
- 672 AGREE-Appraisal of Guidelines for Research and Evaluation II
- 673 PROSPERO-The International Prospective Register of Systematic Reviews
- 674 SARS-CoV-2- severe acute respiratory syndrome coronavirus 2
- 675 COVID-19-Coronavirus Disease
- 676 PRISMA-Preferred Reporting Items for Systematic Reviews and Meta-Analyses
- 677 CADTH-Canadian Agency for Drugs and Technologies in Health
- 678 ISARIC- International Severe Acute Respiratory and Emerging Infection Consortium

- 679 WHO-World Health Organisation
- 680 PAHO-Pan American Health Organisation
- 681 HIV-Human Immunodeficiency Virus
- 682 IQR-Interquartile range
- 683 WHOSEA-World Health Organisation Southeast Asia
- 684 ACCAR-Pan-American League of Associations for Rheumatology-Central American Caribbean and
- 685 Andean Rheumatology Association
- 686 BCDC-Bangladesh Centre for Disease Control
- 687 BMS-Bolivia Ministerio De Salud
- 688 BSR-Brazilian Society of Rheumatology
- 689 BZLMS-Brasil Ministério da Saúde
- 690 CDC-Centers for Disease Control and Prevention
- 691 CMS-Chile Ministerio De Salud
- 692 CRMS-Costa Rica Ministerio De Salud
- 693 DRMSP-República Dominicana Ministerio de Salud Pública
- 694 EMS-Ecuador Ministerio De Salud
- 695 ESMS-El Salvador Ministerio De Salud
- 696 GMS-Guatemala Ministerio De Salud
- 697 IMOH-India Ministry of Health
- 698 JIMA-Journal of Indian Medical Association
- 699 MMS-Mexico Ministerio De Salud
- 700 MS-Medscape
- 701 PHE-Public Health England
- 702 PMS-Peru Ministerio De Salud
- 703 PMSP-Paraguay Ministerio de Salud
- 704 PRMS-Puerto Rico *Ministerio* De Salud

- 705 PUK-Patient UK
- 706 RSMBT-Revista da Sociedade Brasileira de Medicine Tropical
- 707 SMOH-Spain Ministry of Health
- 708 SPLIF-Société de Pathologie Infectieuse de Langue Française
- 709 UTD-UptoDate
- 710 NSAIDs-Non-Steroidal Anti-inflammatory Drugs
- 711 RAPID3-Routine Assessment of Patient Index Data 3
- 712 DAS28-Disease Activity Score-28
- 713 DN4-Douleur Neuropathique 4
- 714 DMARD- Disease Modifying Anti-rheumatic Drugs
- 715 MTCT-mother-to-child transmission
- 716 RCT-Randomised Control Trial
- 717 MTX-Methotrexate
- 718 HCQ-Hydroxychloroquine
- 719 R-Recommended
- 720 NS- Not Stated
- 721 RA- Recommended to avoid
- 722

723 References

- 1. Rodrigues Faria N, Lourenço J, Marques de Cerqueira E, Maia de Lima M, Pybus O, Carlos Junior
- Alcantara L. Epidemiology of Chikungunya Virus in Bahia, Brazil, 2014-2015. PLoS Curr. 2016
- 726 Feb 1;8:ecurrents.outbreaks.c97507e3e48efb946401755d468c28b2.
- Suhrbier A. Rheumatic manifestations of chikungunya: emerging concepts and interventions. Nat
 Rev Rheumatol. 2019 Oct;15(10):597–611.

729	3.	Gould EA, Higgs S	. Impact of climate	change and other factors	on emerging arbovirus diseases.
-----	----	-------------------	---------------------	--------------------------	---------------------------------

730 Trans R Soc Trop Med Hyg. 2009 Feb;103(2):109–21.

731 4. Tjaden NB, Suk JE, Fischer D, Thomas SM, Beierkuhnlein C, Semenza JC. Modelling the effects of

732global climate change on Chikungunya transmission in the 21st century. Sci Rep. 2017 Jun

733 19;7(1):3813.

734 5. Nsoesie EO, Kraemer MU, Golding N, Pigott DM, Brady OJ, Moyes CL, et al. Global distribution
735 and environmental suitability for chikungunya virus, 1952 to 2015. Eurosurveillance. 2016 May
736 19;21(20):30234.

6. Leta S, Beyene TJ, De Clercq EM, Amenu K, Kraemer MUG, Revie CW. Global risk mapping for
major diseases transmitted by Aedes aegypti and Aedes albopictus. Int J Infect Dis IJID Off Publ Int
Soc Infect Dis. 2018 Feb;67:25–35.

- 740 7. Projected change in the climatic suitability for Chikungunya transmission European Environment
 741 Agency [Internet]. [cited 2022 Feb 16]. Available from: https://www.eea.europa.eu/data-and 742 maps/figures/projected-change-in-the-climatic
- 743 8. Cunha RV da, Trinta KS. Chikungunya virus: clinical aspects and treatment A Review. Mem Inst
 744 Oswaldo Cruz. 2017 Aug;112(8):523–31.

9. Simon F, Javelle E, Cabie A, Bouquillard E, Troisgros O, Gentile G, et al. French guidelines for the
management of chikungunya (acute and persistent presentations). November 2014. Med Mal Infect.
2015 Jul;45(7):243–63.

- 10. Sissoko D, Malvy D, Ezzedine K, Renault P, Moscetti F, Ledrans M, et al. Post-Epidemic
- 749 Chikungunya Disease on Reunion Island: Course of Rheumatic Manifestations and Associated
- Factors over a 15-Month Period. PLoS Negl Trop Dis. 2009 Mar 10;3(3):e389.

751	11.	Soumahoro M-K, Boelle P-Y, Gaüzere B-A, Atsou K, Pelat C, Lambert B, et al. The Chikungunya
752		Epidemic on La Réunion Island in 2005–2006: A Cost-of-Illness Study. PLoS Negl Trop Dis. 2011
753		Jun 14;5(6):e1197.

12. Bower H, Karsany M el, Adam AAAH, Idriss MI, Alzain MA, Alfakiyousif MEA, et al.

- 755 "Kankasha" in Kassala: A prospective observational cohort study of the clinical characteristics,
- epidemiology, genetic origin, and chronic impact of the 2018 epidemic of Chikungunya virus

757 infection in Kassala, Sudan. PLoS Negl Trop Dis. 2021 Apr 30;15(4):e0009387.

- 13. Dorléans F, Hoen B, Najioullah F, Herrmann-Storck C, Schepers KM, Abel S, et al. Outbreak of
- 759 Chikungunya in the French Caribbean Islands of Martinique and Guadeloupe: Findings from a

Hospital-Based Surveillance System (2013-2015). Am J Trop Med Hyg. 2018 Jun;98(6):1819–25.

- 14. Economopoulou A, Dominguez M, Helynck B, Sissoko D, Wichmann O, Quenel P, et al. Atypical
 Chikungunya virus infections: clinical manifestations, mortality and risk factors for severe disease
 during the 2005-2006 outbreak on Réunion. Epidemiol Infect. 2009 Apr;137(4):534–41.
- 15. Reisinger EC, Tschismarov R, Beubler E, Wiedermann U, Firbas C, Loebermann M, et al.
- 765 Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-
- 766 CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial. Lancet
- 767 Lond Engl. 2019 Dec 22;392(10165):2718–27.

Folegatti PM, Harrison K, Preciado-Llanes L, Lopez FR, Bittaye M, Kim YC, et al. A single dose of
ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a
phase 1 clinical trial. Nat Commun. 2021 Jul 30;12(1):4636.

17. Zaid A, Gérardin P, Taylor A, Mostafavi H, Malvy D, Mahalingam S. Chikungunya Arthritis:

772 Implications of Acute and Chronic Inflammation Mechanisms on Disease Management. Arthritis

773 Rheumatol Hoboken NJ. 2018 Apr;70(4):484–95.

774	18.	Seelig F, Bezerra H, Cameron M, Hii J, Hiscox A, Irish S, et al. The COVID-19 pandemic should
775		not derail global vector control efforts. PLoS Negl Trop Dis. 2020 Aug 31;14(8):e0008606.
776	19.	Wilder-Smith A, Tissera H, Ooi EE, Coloma J, Scott TW, Gubler DJ. Preventing Dengue
777		Epidemics during the COVID-19 Pandemic. Am J Trop Med Hyg. 2020 Aug;103(2):570–1.
778	20.	Garritty C, Gartlehner G, Nussbaumer-Streit B, King VJ, Hamel C, Kamel C, et al. Cochrane Rapid
779		Reviews Methods Group offers evidence-informed guidance to conduct rapid reviews. J Clin
780		Epidemiol. 2021 Feb;130:13–22.
781	21.	Moher D, Liberati A, Tetzlaff J, Altman DG, Group TP. Preferred Reporting Items for Systematic
782		Reviews and Meta-Analyses: The PRISMA Statement. PLOS Med. 2009 Jul 21;6(7):e1000097.
783	22.	Andrew Dagens, Peter Horby, Shevin Jacobs, Lucille Blumberg, Jonathan Sterne, Henry Kyobe-
784		Basa, Tom Fletcher, Louise Sigfrid. A systematic review of the availability, quality and inclusivity
785		of supportive care guidelines in the management of high consequence infectious disease [Internet].
786		[cited 2021 Dec 21]. Available from:
787		https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=167361&VersionID=1302745
788	23.	Canadian Agency for Drugs and Technologies in Health. Strings attached: CADTH database search
789		filters [Internet]. 2021 [cited 2022 Feb 17]. Available from: https://www.cadth.ca/strings-attached-
790		cadths-database-search-
791		filters#:~:text=When%20using%20the%20CADTH%20search,Ottawa%3A%20CADTH%3B%202
792		021.
793	24.	International Severe Acute Respiratory and emerging Infection Consortium [Internet]. ISARIC.
794		[cited 2022 Feb 16]. Available from: https://isaric.org/

37

- 795 25. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for
 796 systematic reviews. Syst Rev. 2016 Dec;5(1):210.
- 26. Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. AGREE II:
- advancing guideline development, reporting and evaluation in health care. Can Med Assoc J. 2010
- 799 Dec 14;182(18):E839–42.
- 800 27. Wickham H. ggplot2: Elegant Graphics for Data Analysis [Internet]. Springer-Verl N Y [Internet].
 801 2016; Available from: https://ggplot2.tidyverse.org
- 802 28. Tableau (version. 9.1). J Med Libr Assoc JMLA. 2016 Apr;104(2):182–3.
- 803 29. Nava AC, Barba CAP, Mendoza AC, Velasco . Omar Flores, Benavides RR, Pérez CGR. Bolivian
- 804 Ministry of Health and Sports Dengue, Zika and Chikungunya Surveillance and Control Area
- 805 [Internet]. MINISTERIO DE SALUD; 2015 [cited 2021 Dec 10]. Available from:
- 806 https://www.minsalud.gob.bo/38-libros-y-normas/fichas-bibliograficas/1574-area-dengue
- 807 30. Public Health England. Chikungunya [Internet]. The characteristics, symptoms, diagnosis and

epidemiology of chikungunya. 2014 [cited 2021 Dec 10]. Available from:

- 809 https://www.gov.uk/guidance/chikungunya
- 810 31. Harding M, Willacy H. Chikungunya Fever; Chikungunya Virus information. Patient [Internet].
- 811 2015 [cited 2021 Dec 10]. Available from: https://patient.info/doctor/chikungunya-fever-pro
- 812 32. Miner Jonathan; Lenschow Deborah; Wilson Mary. Chikungunya fever: Treatment and prevention
- 813 [Internet]. 2020. Available from: https://www.uptodate.com/contents/chikungunya-fever-treatment814 and-prevention
- 815 33. Brazil Ministry of Health. Chikungunya Manejo Clínico [Internet]. [cited 2022 Feb 17]. Available
 816 from: https://bvsms.saude.gov.br/bvs/publicacoes/chikungunya_manejo_clinico.pdf

- 817 34. Natesan SK, Chandrasekar PH. Chikungunya Virus Workup: Approach Considerations, Serological
- 818 Testing, Viral Culture [Internet]. 2019 [cited 2021 Dec 10]. Available from:
- 819 https://emedicine.medscape.com/article/2225687-workup
- 820 35. Salud CRM de, Social CC de S. Chikungunya. Protocolo de vigilancia y manejo clínico. 2014 Jul
- 821 [cited 2021 Dec 6]; Available from: http://repositorio.binasss.sa.cr/xmlui/handle/20.500.11764/3719
- **822** 36. Clinical Evaluation & Disease | Chikungunya virus | CDC [Internet]. Centres for Disease Control
- and Prevention. 2018 [cited 2021 Dec 10]. Available from:
- 824 https://www.cdc.gov/chikungunya/hc/clinicalevaluation.html
- 825 37. Journal of Indian Medical Association; Clinical recommendations of on management of seasonal
- and acute febrile infection [Internet]. [cited 2022 Feb 17]. Available from: https://ima-
- 827 india.org/ima/pdfdata/JIMA-2020/JIMA-March-2020.pdf
- 828 38. República Dominicana M de SP. Guía de manejo clínico para la infección por el virus Chikungunya
- 829 (chikv). 2014 May [cited 2022 Feb 17]; Available from:
- 830 http://repositorio.ministeriodesalud.gob.do//handle/123456789/42
- 831 39. Arranz Izquierdo JPE, Sanidad SE de M de F y C (semFYC) SE de MG y de F (SEMG) SE de M de
- 832 AP (SEMERGEN) EM de. Guía de manejo en Atención Primaria de pacientes con Dengue,
- 833 Chikungunya y Zika. 2006 [cited 2021 Dec 10]; Available from:
- 834 http://www.msssi.gob.es/profesionales/saludPublica/ccayes/alertasActual/DocsZika/ETV3_Guia_m
- 835 anejo_Atencion_Primaria_Marzo2016.pdf
- 40. Guía de práctica clínica para la atención de casos de fiebre chikungunya en el Perú: Guía técnica
- 837 [Internet]. Ministry of Health. 2015 [cited 2021 Dec 10]. Available from:
- 838 https://www.gob.pe/institucion/minsa/informes-publicaciones/320810-guia-de-practica-clinica-para-
- 839 la-atencion-de-casos-de-fiebre-chikungunya-en-el-peru-guia-tecnica

- 840 41. Guidelines for Clinical Management of the Disease Produced by the Chikungunya Virus [Internet].
- 841 [cited 2022 Feb 17]. Available from:
- 842 https://iris.paho.org/bitstream/handle/10665.2/10106/GUIA%20chikungunya%2019-03-
- 843 15.pdf?sequence=1&isAllowed=y
- 42. WHO office for South East Asia. Guidelines on Clinical Management of Chikungunya Fever
- [Internet]. World Health Organisation. 2008 [cited 2021 Dec 10]. Available from:
- 846 https://www.who.int/publications-detail-redirect/guidelines-on-clinical-management-of-
- 847 chikungunya-fever

848 43. MENJIVAR EV, FIALLOS EAE, TICAS JOR. Lineamientos técnicos para la prevención y control

- de la fiebre Chikungunya [Internet]. MINISTERIO DE SALUD DE EL SALVADOR; 2014 [cited
- 850 2021 Dec 10]. Available from:
- 851 https://www.salud.gob.sv/archivos/pdf/promocion_salud/material_educativo/campana_chikungunya
 852 /Lineamientos Chikungunya2014.pdf
- 853 44. India Ministry of Health. National Guideline for Clinical Managaemnt of Chikungunya [Internet].
- 854 2016 [cited 2021 Dec 10]. Available from:
- 855 https://nvbdcp.gov.in/WriteReadData/1892s/77728737401531912419.pdf
- 45. National guideline on clinical management of chikungunya fever structured online medical academy
- 857 [Internet]. Disease Control unit (CDC) Directorate General of Health Services (DGHS),
- Bangladesh; 2017 [cited 2021 Dec 10]. Available from: http://www.rcmc.com.bd/wp-
- 859 content/uploads/2019/01/Chikungunya.pdf
- 46. Monge P, Vega JM, Sapag AM, Moreno I, Montúfar R, Khoury V, et al. Pan-American League of
- 861 Associations for Rheumatology-Central American, Caribbean and Andean Rheumatology
- 862 Association Consensus-Conference Endorsements and Recommendations on the Diagnosis and

- 863 Treatment of Chikungunya-Related Inflammatory Arthropathies in Latin America. J Clin
- Rheumatol Pract Rep Rheum Musculoskelet Dis. 2019 Mar;25(2):101–7.
- 865 47. Organization PAH. Preparedness and Response for Chikungunya Virus: Introduction in the
- Americas [Internet]. PAHO; 2011 [cited 2021 Dec 6]. Available from:
- https://iris.paho.org/handle/10665.2/4009
- 868 48. Ecuador Ministry of Health. Preparedness and Response to the Virus Chikungunya in Ecuador
- 869 [Internet]. [cited 2022 Feb 17]. Available from:
- 870 https://www.salud.gob.sv/archivos/pdf/promocion_salud/material_educativo/campana_chikungunya
- 871 /Lineamientos_Chikungunya2014.pdf
- 49. Mexico Ministerio De Salud; Prevention diagnosis and treatment of chikungunya [Internet]. [cited
- 873 2022 Feb 17]. Available from: https://www.gob.mx/cms/uploads/attachment/file/121729/757-
- 874 GER.compressed.compressed.pdf
- 875 50. PUERTO RICO Departmento De Salud. Protocolo manejo y control de chikungunya [Internet].
- 876 2014. Available from: https://www.salud.gov.pr/
- 877 51. Marques CDL, Duarte ALBP, Ranzolin A, Dantas AT, Cavalcanti NG, Gonçalves RSG, et al.

878 Recommendations of the Brazilian Society of Rheumatology for the diagnosis and treatment of
879 chikungunya fever. Part 2 - Treatment. Rev Bras Reumatol. 2017;57:s438–51.

- 880 52. World Health Organisation; Tool for the diagnosis and care of patients with suspected arboviral
- diseases [Internet]. World Health Organisation. 2017 [cited 2021 Dec 10]. Available from:
- 882 https://www.who.int/publications/i/item/tool-for-the-diagnosis-and-care-of-patients-with-suspected-
- 883 arboviral-diseases

- 53. Chile Ministry of Health. Technical guidance for the diagnosis and clinical management of
- arbovirosis: dengue, chikungunya, zika and yellow fever [Internet]. MINISTERIO DE SALUD;

886 2018 [cited 2021 Dec 10]. Available from:

- 887 https://corporacionbiologica.info/microbiologia/orientacion-tecnica-para-el-diagnostico-y-manejo-
- 888 clinico-de-arbovirosis-dengue-chikungunya-zika-y-fiebre-amarilla-pdf/
- 889 54. Brito CAA de, Marques CDL, Falcão MB, Cunha RV da, Simon F, Valadares LD de A, et al.
- 890 Update on the treatment of musculoskeletal manifestations in chikungunya fever: a guideline. Rev
- Soc Bras Med Trop [Internet]. 2020 Jul 31 [cited 2021 Dec 6];53. Available from:
- 892 http://www.scielo.br/j/rsbmt/a/QkJVqzXqTCH8j9NFSwcT9Zh/?lang=en
- 893 55. Salud OP de la. Guía Práctica para el Manejo Clínico de Dengue y Chikungunya; Guía para el
- primero, segundo y tercer nivel de atención [Internet]. OPS; 2015 [cited 2021 Dec 10]. Available
 from: https://iris.paho.org/handle/10665.2/54558
- 896 56. Bettis AA, Jackson ML, Yoon I-K, Breugelmans JG, Goios A, Gubler DJ, et al. The global
- epidemiology of chikungunya from 1999 to 2020: A systematic literature review to inform the
 development and introduction of vaccines. PLoS Negl Trop Dis. 2022 Jan 12;16(1):e0010069.
- Padmakumar B, Jayan JB, Menon RM, Krishnankutty B, Payippallil R, Nisha RS. Comparative
 evaluation of four therapeutic regimes in chikungunya arthritis: a prospective randomized parallelgroup study. Indian J Rheumatol. 2009 Jul 1;4(3):94.
- Simon F, Parola P, Grandadam M, Fourcade S, Oliver M, Brouqui P, et al. Chikungunya infection:
 an emerging rheumatism among travelers returned from Indian Ocean islands. Report of 47 cases.
 Medicine (Baltimore). 2007 May;86(3):123–37.
- 905 59. Parashar D, Cherian S. Antiviral Perspectives for Chikungunya Virus. BioMed Res Int.
 906 2014;2014:631642.

- 907 60. Simon F, Javelle E, Oliver M, Leparc-Goffart I, Marimoutou C. Chikungunya Virus Infection. Curr
 908 Infect Dis Rep. 2011;13(3):218–28.
- 909 61. Schwartz O, Albert ML. Biology and pathogenesis of chikungunya virus. Nat Rev Microbiol. 2010
 910 Jul;8(7):491–500.
- 911 62. Renault P, Solet J-L, Sissoko D, Balleydier E, Larrieu S, Filleul L, et al. A major epidemic of
 912 chikungunya virus infection on Reunion Island, France, 2005-2006. Am J Trop Med Hyg. 2007
 913 Oct;77(4):727–31.
- 914 63. Evans-Gilbert T. Vertically transmitted chikungunya, Zika and dengue virus infections: The
- 915 pathogenesis from mother to fetus and the implications of co-infections and vaccine development.
- 916 Int J Pediatr Adolesc Med. 2020 Sep;7(3):107–11.
- 917 64. Charlier C, Beaudoin M-C, Couderc T, Lortholary O, Lecuit M. Arboviruses and pregnancy:
 918 maternal, fetal, and neonatal effects. Lancet Child Adolesc Health. 2017 Oct;1(2):134–46.
- 919 65. Gérardin P. Chikungunya fever in children: From epidemiology to treatment. Med Ther Pediatr.
 920 2012 Apr 1:15:49–56.
- 921 66. Neto ASL, Sousa GS, Nascimento OJ, Castro MC. Chikungunya-attributable deaths: A neglected
 922 outcome of a neglected disease. PLoS Negl Trop Dis. 2019 Sep 12;13(9):e0007575.
- 923 67. Martí-Carvajal A, Ramon-Pardo P, Javelle E, Simon F, Aldighieri S, Horvath H, et al. Interventions
- 924 for treating patients with chikungunya virus infection-related rheumatic and musculoskeletal
- disorders: A systematic review. PloS One. 2017;12(6):e0179028.
- 926 68. Ravindran V, Alias G. Efficacy of combination DMARD therapy vs. hydroxychloroquine
- 927 monotherapy in chronic persistent chikungunya arthritis: a 24-week randomized controlled open
- **928** label study. Clin Rheumatol. 2017 Jun;36(6):1335–40.

- 929 69. UpToDate: Evidence-based Clinical Decision Support [Internet]. [cited 2022 Feb 17]. Available
- 930 from: https://www.wolterskluwer.com/en/solutions/uptodate

- . .



Figure 1: PRISMA diagram

Figure 1



Figure 2: Chikungunya outbreaks (1999-2020) and geographic distribution of identified CMGs

The blue shading shows human Chikungunya outbreaks documented as of 1999-2020.⁵⁶ The green dots represent countries with a chikungunya clinical management guidelines (CMGs) and the numbers identified. Additionally, there were three global CMGs produced by the World Health Organisation (WHO), Medscape and Up-to-date, and three regional CMGs produced by the Pan-American Health Organisation (PAHO), WHO

South-East Asia (WHOSEA) and Pan-American League of Associations for Rheumatology-Central American Caribbean and Andean Rheumatology Association (ACCAR).

(Map adapted from Bettis, A.A and Jackson L.M et al., Plos NTD, 202256)





Each violin plot portrays the individual scores of the CMGs in each domain. Each dot represents a CMG proportional score per domain. The width of each curve represents the frequency of CMG scoring in each region.

Figure 3